Clinical trialNCT02222714CompletedPhase 2Interventional

Safety Evaluation of 3K3A-APC in Ischemic Stroke

SponsorZZ Biotech, LLCEnrollment110Ischemic Stroke

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was to evaluate the safety, pharmacokinetics (PK) and preliminary efficacy of multiple ascending intravenous doses of 3K3A-APC, a Recombinant Variant of Human activated protein C (APC), in in the treatment of acute ischemic stroke following treatment with recombinant tissue plasminogen activator (tPA), mechanical thrombectomy or both.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Patrick D. Lyden, MD
Cedars-Sinai Medical Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stroke Center
Los Angeles, California, United States
Stroke Center
Chicago, Illinois, United States
Stroke Center
Kansas City, Kansas, United States
Stroke Center
Boston, Massachusetts, United States
Stroke Center
St Louis, Missouri, United States
Stroke Center
Buffalo, New York, United States
Stroke Center
New York, New York, United States
Stroke Center
Rochester, New York, United States
Stroke Center
Cincinnati, Ohio, United States
Stroke Center
Columbus, Ohio, United States
Stroke Center
Pittsburgh, Pennsylvania, United States
Stroke Center
Nashville, Tennessee, United States
Stroke Center
Dallas, Texas, United States
Stroke Center
Salt Lake City, Utah, United States
Stroke Center
Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

3K3A-APCPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Oct 2014
Primary completion: 18 Apr 2017
Completion: 29 Jun 2017
Last update posted: 8 Nov 2018
Registered enrollment: 110
Registry id: NCT02222714

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.